Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
182.90
+4.80 (2.70%)
Nov 21, 2024, 1:38 PM EST - Market open
Krystal Biotech Revenue
Krystal Biotech had revenue of $83.84M in the quarter ending September 30, 2024, with 879.91% growth. This brings the company's revenue in the last twelve months to $241.52M, up 2,722.80% year-over-year. In the year 2023, Krystal Biotech had annual revenue of $50.70M.
Revenue (ttm)
$241.52M
Revenue Growth
+2,722.80%
P/S Ratio
20.98
Revenue / Employee
$1,054,668
Employees
229
Market Cap
5.26B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Select Medical Holdings | 6.97B |
Stevanato Group | 1.22B |
Waystar Holding | 906.14M |
Ionis Pharmaceuticals | 803.07M |
Inspire Medical Systems | 755.59M |
ADMA Biologics | 382.81M |
PROCEPT BioRobotics | 199.84M |
Arcellx | 155.82M |
KRYS News
- 15 days ago - Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire
- 16 days ago - Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024 - GlobeNewsWire
- 5 weeks ago - Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On - Seeking Alpha
- 2 months ago - Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade) - Seeking Alpha